Drug therapy development

Analogous to the recent progress in antidepressant and antipsychotic drug therapy development the pharmacotherapy of bipolar disorder is also experiencing major advances. Data on the efficacy of mood stabilizers for bipolar disorder focus on the following ... 

The pharmacist formulates plans to effect the desired outcome. The plans may include, but are not limited to, work with the patient as well as with other health providers to develop a patient-specific drug therapy protocol or to modify prescribed drug therapy, develop and/or implement drug therapy monitoring mechanisms, recommend nutritional or dietary modifications, add non-prescription medications or non-drug treatments, re-... 

While advances in the symptomatic drug therapy (summarized below) have certainly improved the lives of many Parkinson patients, the goal of current research is to develop treatments that can prevent, retard or reverse the death of dopaminergic neurons in the substantia nigra pats compacta (and of other neurons involved in the pathogenesis of Parkinson s disease not mentioned in this essay). 

The PAR family represents a novel target for drug therapy. Therapeutic approaches with most clinical benefit may rely upon the development of both agonists and antagonists, either of which could be utilised dqiending upon the disease condition [3]. 

Those at risk of developing tuberculosis (eg, those with Hodgkin s disease, severe diabetes mellitus, leukemia, and other serious illnesses and those receiving corticosteroids or drug therapy for a malignancy)... 

Before giving a nonnarcotic analgesic to a patient, the nurse assesses the type, onset, and location of the pain. It is important to determine if this problem is different in any way from previous episodes of pain or discomfort. If the patient is receiving a nonnarcotic analgesic for an arthritic or musculoskeletal disorder or soft tissue inflammation, the nurse should examine the joints or areas involved. The appearance of the skin over the joint or affected area or any limitation of motion is documented. The nurse evaluates the patient s ability to carry out activities of daily living. This important information is used to develop a care plan, as well as to evaluate the response to drug therapy. 

When developing a teaching plan for the patient and family, tlie nurse emphasizes the importance of uninterrupted drug therapy. The nurse allows the patient and family time to ask questions. The nurse explores any problems that appear to be associated with tlie prescribed drug regimen and then reports them to tlie primary health care provider. The nurse reviews tlie purpose of tlie drug therapy with tlie patient and family, as well as the adverse reactions that may occur. 

Once a euthyroid state is achieved, tlie primary health care provider may add a thyroid hormone to tlie therapeutic regimen to prevent or treat hypothyroidism, which may develop slowly during long-term antithyroid drug therapy or after administration of 131I. 

The overall objective of clinical trials is to establish a drug therapy that is safe and effective in humans, to the extent that the risk-benefit relationship is acceptable. The ICH process has developed an internationally accepted definition of a clinical trial as Any investigation in human subjects intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of one or more investigational medicinal product(s), and/or to identify any adverse reactions to one or more investigational medicinal product(s) and/or to study absorption, distribution, metabolism and excretion of one or more investigational medicinal product(s) with the object of ascertaining its (their) safety and/or efficacy. ... 

Develop drug therapy treatment plans for management of the specific arrhythmia that the patient is experiencing sinus bradycardia, AV nodal blockade, AF, PSVT, VPDs, VT (including torsades de pointes), or VF. 

Develop specific drug therapy monitoring plans for the treatment plan implemented. Monitoring includes assessment of symptoms, ECG, adverse effects of drugs, and potential drug interactions. 

Immunosuppressants such as azathioprine or 6-mercaptopurine can be used for unresponsive patients or those who develop corticosteroid dependency. Remission may be maintained in up to 58% of patients after 5 years of treatment.1,25 Intermittent infliximab dosing (5 mg/kg IV every 8 weeks) may be used to maintain disease remission and reduce the need for corticosteroids in patients with moderate to severe UC. Colectomy is an option for patients with progressive disease who cannot be maintained on drug therapy alone. 

Develop a plan to assess the effectiveness of drug therapy during the first 12 weeks. 

---